Tyrosine kinase inhibitors have altered the clinical prognosis of chronic myeloid leukemia over the past two decades. However, standard fixed-dose regimens frequently fail to account for significant pharmacokinetic variations among individual patients. Consequently, clinicians increasingly turn to TKI therapeutic drug monitoring to optimize target exposure, prevent treatment failure, and avoid dose-limiting toxicities. A new clinical trial now demonstrates the feasibility and clinical utility of patient-led capillary blood sampling performed in the comfort of home.

Overcoming Logistical Hurdles in Tyrosine Kinase Inhibitor Therapy

Oral targeted therapies require strict long-term adherence and consistent systemic exposure. Currently, conventional venous blood sampling poses substantial logistical barriers for busy oncology outpatients. Patients must travel to tertiary care hospitals early in the morning before taking their medication. Consequently, this inconvenience often leads to missed trough measurements and incomplete pharmacokinetic evaluations. In addition, standard venipuncture causes discomfort and consumes valuable healthcare resources.

Therefore, dried blood microsampling technologies offer a compelling alternative. Specifically, volumetric absorptive microsampling captures an exact, fixed capillary blood volume from a simple finger prick. Because the dried polymeric tip absorbs an accurate blood volume regardless of hematocrit variations, it overcomes the classic hematocrit bias observed in conventional dried blood spots. As a result, patients can easily perform reliable sampling at home right before their scheduled daily dose.

Assessing Patient Experience and Analytical Feasibility at Home

Researchers conducted a prospective clinical investigation evaluating home-based microsampling for patients receiving dasatinib or imatinib. The study enrolled forty-nine chronic myeloid leukemia patients, comprising thirty-two individuals on dasatinib and seventeen on imatinib. Clinicians initially trained participants on proper finger-prick collection techniques. Subsequently, patients collected replicate capillary samples at home every three days on four separate mornings immediately before taking their tyrosine kinase inhibitor.

Patients subsequently dispatched their dried sampling devices to the central laboratory using regular prepaid postal mail. In addition, participants completed structured survey questionnaires to evaluate user satisfaction and ergonomic feasibility. Overall, the investigative team received forty-seven complete sample sets. Notably, ninety percent of all home-collected samples met strict laboratory quality criteria, displaying excellent analytical reproducibility between replicates. Furthermore, participant feedback showed overwhelming enthusiasm, confirming that self-sampling seamlessly integrates into routine daily life.

Evaluating Interpatient and Intrapatient Pharmacokinetic Variability

The study yielded pivotal pharmacokinetic insights regarding real-world tyrosine kinase inhibitor exposure. Confirming previous historical observations, the analytical data demonstrated pronounced interpatient variability in both dasatinib and imatinib trough levels. Furthermore, the longitudinal protocol uncovered substantial intrapatient variability across consecutive collection days. Within the same individual, trough concentrations fluctuated markedly over short intervals.

Importantly, these intra-individual fluctuations were exceptionally prominent among patients receiving dasatinib. Because dasatinib has a short terminal elimination half-life of three to five hours, minor alterations in daily administration timing produce pronounced shifts in trough concentrations. Conversely, imatinib exhibits a longer elimination half-life of approximately eighteen hours, yielding relatively more stable exposure profiles. Consequently, single-point plasma evaluations may fail to represent true steady-state drug exposure, emphasizing the distinct clinical value of serial home-based assessments.

Clinical Value of TKI Therapeutic Drug Monitoring

Establishing consistent target concentrations remains fundamental for achieving deep molecular responses in chronic myeloid leukemia. For instance, maintaining an imatinib trough level above one thousand nanograms per milliliter correlates directly with improved cytogenetic and molecular response rates. Conversely, excessively elevated concentrations often trigger severe adverse events, including fluid retention, muscle cramps, and myelosuppression. Therefore, timely dose titration guided by TKI therapeutic drug monitoring directly enhances safety and efficacy.

Similarly, dasatinib exposure-response relationships dictate tight concentration control. While achieving sufficient peak concentrations promotes rapid BCR-ABL1 transcript reduction, persistently elevated dasatinib trough concentrations correlate strongly with pleural effusion development. Consequently, regular pharmacokinetic monitoring empowers hematologists to reduce dosages safely in responding patients. Thus, individualized dosing strategies prevent irreversible pulmonary complications without sacrificing deep molecular remissions.

Decentralized Oncology and Future Directions in Precision Medicine

Decentralized laboratory monitoring represents a critical evolution toward patient-centric oncology care. By moving routine pharmacokinetic surveillance into domestic environments, clinicians reduce hospital congestion and eliminate unnecessary travel expenses for patients. Moreover, this approach facilitates frequent longitudinal sampling, allowing oncologists to rapidly identify drug-drug interactions, non-adherence, or absorption anomalies. Hence, real-time exposure feedback enables proactive dosage modifications rather than delayed, reactive responses.

Nevertheless, wider clinical implementation requires robust regional logistics and standardized laboratory automation. Pathologists must validate high-throughput liquid chromatography-tandem mass spectrometry workflows capable of extracting drugs efficiently from dried matrices. Additionally, clinical teams must provide comprehensive initial patient training to minimize procedural errors. As oncologists manage leukemia as a chronic condition, remote monitoring platforms will play an indispensable role in maintaining lifelong therapeutic efficacy.

Frequently Asked Questions

How does volumetric absorptive microsampling overcome hematocrit bias?

Conventional dried blood spots often suffer from variable blood spreading caused by fluctuating hematocrit levels. In contrast, volumetric absorptive microsampling utilizes an engineered hydrophilic porous polymer tip. This innovative tip wicks an exact, predetermined volume of blood within seconds, regardless of individual patient hematocrit. Consequently, the laboratory extracts a uniform, highly reproducible blood volume, ensuring precise quantitative drug concentration measurements.

Why do dasatinib trough concentrations exhibit higher variability than imatinib?

Dasatinib possesses a very short elimination half-life of only three to five hours. Therefore, slight deviations in the exact timing of medication intake or sample collection significantly alter measured trough levels. In contrast, imatinib displays a prolonged half-life of roughly eighteen hours. Consequently, imatinib systemic concentrations remain comparatively stable across daily dosing intervals, resulting in less daily intra-individual fluctuation.

How does routine therapeutic drug monitoring improve long-term CML management?

Routine therapeutic drug monitoring enables physicians to personalize oral chemotherapy dosages based on true biological exposure rather than empirical body weight formulas. Consequently, clinicians can identify under-exposed patients who risk disease relapse or therapeutic failure. Furthermore, monitoring detects drug accumulation early, allowing preventative dose reductions that protect patients from chronic toxicities such as pleural effusions, edema, and severe myelosuppression.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when making treatment decisions. Patient situations vary, and individual clinical factors must be carefully evaluated. Refer to the latest local and national guidelines for clinical practice.

References

1. Verougstraete N et al. Assessment of Interpatient and Intrapatient Variability of Dasatinib and Imatinib Concentrations in Patients With Chronic Myeloid Leukemia via Volumetric Absorptive Microsampling at Home. Ther Drug Monit. 2026 Oct 30. doi: 10.1097/FTD.0000000000001549. PMID: 42962084.
2. Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38(5):645-654.
3. Veringa A, et al. Toward Clinical Implementation of a Volumetric Absorptive Microsampling-Based Method for Dasatinib and Imatinib Therapeutic Drug Monitoring. Ther Drug Monit. 2025 Dec;47(6):780-788.